FindTrial
Sign In

Based on the strategy of metabolomics, the key techniques of diagnosis of ovarian hypofunction and efficacy evaluation of kidney-tonifying method were studied

Based on the strategy of metabolomics, the key techniques of diagnosis of ovarian hypofunction and efficacy evaluation of kidney-tonifying method were studied

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR1900002861
Enrollment
Unknown
Registered
2019-12-22
Start date
2019-12-30
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Dysfunction Premature Ovarian Failure

Interventions

Kidney Yin deficiency group:Zuogui Pil
Kidney Yang deficiency group:Yougui Pill
normal group:none

Sponsors

Jiangsu Province Hospital on Integration of Chinese and Western Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
21 Years to 49 Years

Inclusion criteria

Inclusion criteria: normal group 1. Aged 21-49, female; 2. Menstrual color quantity and quality are normal; 3. No serious damage to the heart, liver, kidney or hematopoietic system; 4. Informed consent and voluntary participation. Abnormal group 1. Western medicine meets the diagnosis criteria of ovarian hypofunction and premature ovarian failure, while traditional Chinese medicine meets the diagnosis criteria of kidney-yang deficiency or kidney-yin deficiency. 2. No serious damage to the heart, liver, kidney or hematopoietic system; 3. Informed consent and voluntary participation.

Exclusion criteria

Exclusion criteria: normal group 1. Menstrual color quantity and quality were normal after drug treatment; 2. Patients with obvious heart, brain, blood, neuropsychosis, endometrial cancer, ovarian cancer and other gynecological malignant tumors; 3. Pregnancy or lactation; 4. Drink or use drugs; 5. Other treatments received within 4 weeks. Abnormal group 1. Congenital abnormal development of reproductive organs, or amenorrhea caused by acquired organic lesions and injuries; 2. Pregnancy or lactation; 3. Patients with obvious heart, brain, blood, neuropsychosis and diabetes; 4. Drink or use drugs; 5. Allergic to the research drugs; 6. Patients with polycystic ovary syndrome; 7. Patients receiving other treatment within 4 weeks.

Design outcomes

Primary

MeasureTime frame
Gynecological B ultrasonic;Serum E2, FSH, LH and AMH levels;Changes in blood metabolomics;—

Secondary

MeasureTime frame
changes in TCM symptom score;blood routine;Stool routine;urine routine;renal function;Liver function;electrocardiography (ECG);Blood and urine HCG;—

Countries

China

Contacts

Public ContactWang Peijuan
chensi8828@163.com+86 13372018822

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026